Wealth Enhancement Advisory Services LLC Invests $41,000 in Nektar Therapeutics (NASDAQ:NKTR)

Wealth Enhancement Advisory Services LLC acquired a new position in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 60,371 shares of the biopharmaceutical company's stock, valued at approximately $41,000.

Several other large investors have also recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Nektar Therapeutics by 12.3% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 730,875 shares of the biopharmaceutical company's stock valued at $680,000 after buying an additional 80,034 shares during the period. Monaco Asset Management SAM lifted its holdings in Nektar Therapeutics by 1.8% in the fourth quarter. Monaco Asset Management SAM now owns 2,032,868 shares of the biopharmaceutical company's stock valued at $1,891,000 after buying an additional 35,648 shares during the period. Sei Investments Co. raised its holdings in Nektar Therapeutics by 50.6% in the fourth quarter. Sei Investments Co. now owns 94,152 shares of the biopharmaceutical company's stock worth $88,000 after purchasing an additional 31,654 shares during the period. JPMorgan Chase & Co. raised its holdings in Nektar Therapeutics by 29.5% in the fourth quarter. JPMorgan Chase & Co. now owns 1,182,995 shares of the biopharmaceutical company's stock worth $1,100,000 after purchasing an additional 269,695 shares during the period. Finally, Wellington Management Group LLP raised its holdings in Nektar Therapeutics by 10.4% in the fourth quarter. Wellington Management Group LLP now owns 522,409 shares of the biopharmaceutical company's stock worth $486,000 after purchasing an additional 49,319 shares during the period. 75.88% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on NKTR. Wall Street Zen lowered shares of Nektar Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday, May 14th. BTIG Research raised their price objective on shares of Nektar Therapeutics from $60.00 to $100.00 and gave the stock a "buy" rating in a report on Tuesday, June 24th. Jefferies Financial Group upgraded shares of Nektar Therapeutics from a "hold" rating to a "buy" rating and raised their price objective for the stock from $15.00 to $30.00 in a report on Friday, April 11th. HC Wainwright raised their price objective on shares of Nektar Therapeutics to $120.00 and gave the stock a "buy" rating in a report on Tuesday, June 24th. Finally, William Blair restated a "market perform" rating on shares of Nektar Therapeutics in a report on Monday, May 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $88.33.

Nektar Therapeutics Stock Performance

Nektar Therapeutics stock traded down $0.09 during mid-day trading on Friday, reaching $25.01. The company's stock had a trading volume of 1,207,020 shares, compared to its average volume of 504,145. The business's 50 day simple moving average is $14.22 and its 200 day simple moving average is $12.90. Nektar Therapeutics has a 12 month low of $6.48 and a 12 month high of $37.38. The company has a market capitalization of $310.37 million, a price-to-earnings ratio of -2.61 and a beta of 0.94.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($3.30) EPS for the quarter, missing analysts' consensus estimates of ($2.70) by ($0.60). Nektar Therapeutics had a negative net margin of 152.49% and a negative return on equity of 329.54%. The firm had revenue of $10.46 million during the quarter, compared to the consensus estimate of $15.61 million. During the same period last year, the business earned ($2.70) EPS. As a group, sell-side analysts expect that Nektar Therapeutics will post -0.72 EPS for the current year.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.